Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
European Radiology|October 20, 2012
Parkinson's disease: diagnostic potential of high-resolution phase difference enhanced MR imaging at 3 TShingo Kakeda, Yukunori Korogi, Tetsuya Yoneda, et al.
European Radiology|August 1, 2015
Quantitative susceptibility mapping in patients with systemic lupus erythematosus: detection of abnormalities in normal-appearing basal gangliaAtsushi Ogasawara, Shingo Kakeda, Keita Watanabe, et al.
The Journal of Experimental Medicine|June 24, 2009
Cardiac 12/15 lipoxygenase-induced inflammation is involved in heart failureYosuke Kayama, Tohru Minamino, Haruhiro Toko, et al.
Internal Medicine (Tokyo, Japan)|August 21, 2022
Importance of the Multimodality Evaluation of a Double-chambered Right Ventricle for Surgical Indications on Admission for Acute Myocardial InfarctionShuhei Aoki, Hiroyuki Takaoka, Ryo Ito, et al.
The Journal of Clinical Investigation|April 22, 2010
Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodentsIppei Shimizu, Tohru Minamino, Haruhiro Toko, et al.
Neuropsychiatric Disease and Treatment|July 26, 2014
COMT Val158Met, but not BDNF Val66Met, is associated with white matter abnormalities of the temporal lobe in patients with first-episode, treatment-naïve major depressive disorder: a diffusion tensor imaging studyKenji Hayashi, Reiji Yoshimura, Shingo Kakeda, et al.
Plos One|February 12, 2014
Abnormal white matter integrity in the corpus callosum among smokers: tract-based spatial statisticsWakako Umene-Nakano, Reiji Yoshimura, Shingo Kakeda, et al.
European Radiology|November 2, 2014
Internal structures of the globus pallidus in patients with Parkinson's disease: evaluation with quantitative susceptibility mapping (QSM)Satoru Ide, Shingo Kakeda, Issei Ueda, et al.
Haematologica|December 22, 2018
Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphomaAdrienne A Phillips, Paul A Fields, Olivier Hermine, et al.
The Lancet. Oncology|August 14, 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialYoun H Kim, Martine Bagot, Lauren Pinter-Brown, et al.
Pageof 9